Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATIFY trial in primary Sjögren’s syndrome
NL-OMON59030Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in primary Sjögren's syndrome comparing Hydroxychloroquine + leflunomide, Hydroxychloroquine + mycophenolate mofetil and Placebo (3 arms). Primary endpoints: STAR response at week 24 and Cohort 2 STAR response at week 24. Started Apr 2022; status: completed.
02
Drugs
hydroxychloroquineleflunomidemycophenolate mofetil
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59030.